165 related articles for article (PubMed ID: 29322935)
41. Lung adenocarcinoma of never smokers and smokers harbor differential regions of genetic alteration and exhibit different levels of genomic instability.
Thu KL; Vucic EA; Chari R; Zhang W; Lockwood WW; English JC; Fu R; Wang P; Feng Z; MacAulay CE; Gazdar AF; Lam S; Lam WL
PLoS One; 2012; 7(3):e33003. PubMed ID: 22412972
[TBL] [Abstract][Full Text] [Related]
42. Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers.
Lee SY; Kim MJ; Jin G; Yoo SS; Park JY; Choi JE; Jeon HS; Cho S; Lee EB; Cha SI; Park TI; Kim CH; Jung TH; Park JY
J Thorac Oncol; 2010 Nov; 5(11):1734-40. PubMed ID: 20881644
[TBL] [Abstract][Full Text] [Related]
43. Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors.
Balko JM; Potti A; Saunders C; Stromberg A; Haura EB; Black EP
BMC Genomics; 2006 Nov; 7():289. PubMed ID: 17096850
[TBL] [Abstract][Full Text] [Related]
44. Effects of germline and somatic events in candidate BRCA-like genes on breast-tumor signatures.
Bodily WR; Shirts BH; Walsh T; Gulsuner S; King MC; Parker A; Roosan M; Piccolo SR
PLoS One; 2020; 15(9):e0239197. PubMed ID: 32997669
[TBL] [Abstract][Full Text] [Related]
45. Characterizing the cancer genome in lung adenocarcinoma.
Weir BA; Woo MS; Getz G; Perner S; Ding L; Beroukhim R; Lin WM; Province MA; Kraja A; Johnson LA; Shah K; Sato M; Thomas RK; Barletta JA; Borecki IB; Broderick S; Chang AC; Chiang DY; Chirieac LR; Cho J; Fujii Y; Gazdar AF; Giordano T; Greulich H; Hanna M; Johnson BE; Kris MG; Lash A; Lin L; Lindeman N; Mardis ER; McPherson JD; Minna JD; Morgan MB; Nadel M; Orringer MB; Osborne JR; Ozenberger B; Ramos AH; Robinson J; Roth JA; Rusch V; Sasaki H; Shepherd F; Sougnez C; Spitz MR; Tsao MS; Twomey D; Verhaak RG; Weinstock GM; Wheeler DA; Winckler W; Yoshizawa A; Yu S; Zakowski MF; Zhang Q; Beer DG; Wistuba II; Watson MA; Garraway LA; Ladanyi M; Travis WD; Pao W; Rubin MA; Gabriel SB; Gibbs RA; Varmus HE; Wilson RK; Lander ES; Meyerson M
Nature; 2007 Dec; 450(7171):893-8. PubMed ID: 17982442
[TBL] [Abstract][Full Text] [Related]
46. Integration of genomic copy number variations and chemotherapy-response biomarkers in pediatric sarcoma.
Cheng L; Pandya PH; Liu E; Chandra P; Wang L; Murray ME; Carter J; Ferguson M; Saadatzadeh MR; Bijangi-Visheshsaraei K; Marshall M; Li L; Pollok KE; Renbarger JL
BMC Med Genomics; 2019 Jan; 12(Suppl 1):23. PubMed ID: 30704460
[TBL] [Abstract][Full Text] [Related]
47. EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics.
Arcila ME; Nafa K; Chaft JE; Rekhtman N; Lau C; Reva BA; Zakowski MF; Kris MG; Ladanyi M
Mol Cancer Ther; 2013 Feb; 12(2):220-9. PubMed ID: 23371856
[TBL] [Abstract][Full Text] [Related]
48. The Genomic Landscape of Pancreatic and Periampullary Adenocarcinoma.
Sandhu V; Wedge DC; Bowitz Lothe IM; Labori KJ; Dentro SC; Buanes T; Skrede ML; Dalsgaard AM; Munthe E; Myklebost O; Lingjærde OC; Børresen-Dale AL; Ikdahl T; Van Loo P; Nord S; Kure EH
Cancer Res; 2016 Sep; 76(17):5092-102. PubMed ID: 27488532
[TBL] [Abstract][Full Text] [Related]
49. Survey and comparative assessments of computational multi-omics integrative methods with multiple regulatory networks identifying distinct tumor compositions across pan-cancer data sets.
Wei Z; Zhang Y; Weng W; Chen J; Cai H
Brief Bioinform; 2021 May; 22(3):. PubMed ID: 32533167
[TBL] [Abstract][Full Text] [Related]
50. Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.
Sun Y; Ren Y; Fang Z; Li C; Fang R; Gao B; Han X; Tian W; Pao W; Chen H; Ji H
J Clin Oncol; 2010 Oct; 28(30):4616-20. PubMed ID: 20855837
[TBL] [Abstract][Full Text] [Related]
51. Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19 784 Diverse Solid Tumors.
Millis SZ; Ikeda S; Reddy S; Gatalica Z; Kurzrock R
JAMA Oncol; 2016 Dec; 2(12):1565-1573. PubMed ID: 27388585
[TBL] [Abstract][Full Text] [Related]
52. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib.
Bean J; Brennan C; Shih JY; Riely G; Viale A; Wang L; Chitale D; Motoi N; Szoke J; Broderick S; Balak M; Chang WC; Yu CJ; Gazdar A; Pass H; Rusch V; Gerald W; Huang SF; Yang PC; Miller V; Ladanyi M; Yang CH; Pao W
Proc Natl Acad Sci U S A; 2007 Dec; 104(52):20932-7. PubMed ID: 18093943
[TBL] [Abstract][Full Text] [Related]
53. Claudin-low-like mouse mammary tumors show distinct transcriptomic patterns uncoupled from genomic drivers.
Fougner C; Bergholtz H; Kuiper R; Norum JH; Sørlie T
Breast Cancer Res; 2019 Jul; 21(1):85. PubMed ID: 31366361
[TBL] [Abstract][Full Text] [Related]
54. Multi-omics of 34 colorectal cancer cell lines - a resource for biomedical studies.
Berg KCG; Eide PW; Eilertsen IA; Johannessen B; Bruun J; Danielsen SA; Bjørnslett M; Meza-Zepeda LA; Eknæs M; Lind GE; Myklebost O; Skotheim RI; Sveen A; Lothe RA
Mol Cancer; 2017 Jul; 16(1):116. PubMed ID: 28683746
[TBL] [Abstract][Full Text] [Related]
55. Exploring the spatiotemporal genetic heterogeneity in metastatic lung adenocarcinoma using a nuclei flow-sorting approach.
Lorber T; Andor N; Dietsche T; Perrina V; Juskevicius D; Pereira K; Greer SU; Krause A; Müller DC; Savic Prince S; Lardinois D; Barrett MT; Ruiz C; Bubendorf L
J Pathol; 2019 Feb; 247(2):199-213. PubMed ID: 30350422
[TBL] [Abstract][Full Text] [Related]
56. Functional genomics identifies specific vulnerabilities in PTEN-deficient breast cancer.
Tang YC; Ho SC; Tan E; Ng AWT; McPherson JR; Goh GYL; Teh BT; Bard F; Rozen SG
Breast Cancer Res; 2018 Mar; 20(1):22. PubMed ID: 29566768
[TBL] [Abstract][Full Text] [Related]
57. Identifying overlapping mutated driver pathways by constructing gene networks in cancer.
Wu H; Gao L; Li F; Song F; Yang X; Kasabov N
BMC Bioinformatics; 2015; 16 Suppl 5(Suppl 5):S3. PubMed ID: 25859819
[TBL] [Abstract][Full Text] [Related]
58. Characterizing genomic differences of human cancer stratified by the TP53 mutation status.
Wang M; Yang C; Zhang X; Li X
Mol Genet Genomics; 2018 Jun; 293(3):737-746. PubMed ID: 29330617
[TBL] [Abstract][Full Text] [Related]
59. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.
Wen S; Dai L; Wang L; Wang W; Wu D; Wang K; He Z; Wang A; Chen H; Zhang P; Dong X; Dong YA; Wang K; Yao M; Wang M
Oncologist; 2019 Nov; 24(11):e1070-e1081. PubMed ID: 30902917
[TBL] [Abstract][Full Text] [Related]
60. Lung adenocarcinomas with HER2-activating mutations are associated with distinct clinical features and HER2/EGFR copy number gains.
Li C; Sun Y; Fang R; Han X; Luo X; Wang R; Pan Y; Hu H; Zhang Y; Pao W; Shen L; Ji H; Chen H
J Thorac Oncol; 2012 Jan; 7(1):85-9. PubMed ID: 22071781
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
